Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nevirapine Resistance Study: Nevirapine Resistance Among HIV-Infected Mothers

This study has been completed.
Sponsor:
Collaborators:
Kamuzu Central Hospital, Lilongwe, Malawi
University of North Carolina
Information provided by:
Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier:
NCT00164762
First received: September 12, 2005
Last updated: September 27, 2007
Last verified: September 2007

September 12, 2005
September 27, 2007
June 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00164762 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Nevirapine Resistance Study: Nevirapine Resistance Among HIV-Infected Mothers
Nevirapine Pharmacodynamics and Resistance Among HIV-Infected Mothers in Lilongwe, Malawi

The purpose of this study is to determine whether the addition of zidovudine (ZDV) and lamivudine (3TC) at the onset of labor and for up to seven days postpartum to single-dose nevirapine (NVP) is associated with a lower prevalence of NVP-resistant HIV compared to single-dose NVP without ZDV+3TC.

The primary purpose of the Nevirapine Resistance Study is to compare nevirapine (NVP) resistance of HIV at two and six weeks postpartum in women who are participating in two different programs currently ongoing in Lilongwe, Malawi. The first program is through the HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health, also known as the Breastfeeding, Antiretrovirals and Nutrition (BAN) Study, a clinical trial where all enrolled women receive zidovudine (ZDV) and lamivudine (3TC) at the onset of labor and for up to seven days postpartum in addition to single-dose nevirapine (NVP). The second program is the Call to Action (CTA) program sponsored by the Malawi Ministry of Health and Population (MOHP) and UNC Project. The aim of the CTA program is to reduce mother to child transmission (MTCT) of HIV by providing women a single dose NVP to be taken at the onset of labor. Study participants are tested for NVP-resistant HIV at two and six weeks postpartum and the prevalence of NVP-resistant virus is compared among the two groups receiving different peripartum anti-retroviral regimens.

Observational
Observational Model: Defined Population
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
HIV Infections
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
126
November 2006
Not Provided

Inclusion Criteria:

  • HIV infected
  • CD4 count > 200 cells/μL
  • ALT < 2.5 x upper limit of normal (ULN)
  • Hemoglobin (Hb) > 7 g/dL
  • Age > 18 years, or <18 years and married (considered emancipated minors in Malawi)
  • Ability to give informed consent
  • Evidence of HIV infection, as documented by 2 positive Enzyme-Linked Immunosorbent Assays (ELISA's); or 1 positive ELISA, and 1 Western blot (WB); or 2 separate concurrent rapid tests. These are the World Health Organization (WHO) acceptable criteria for diagnosing HIV-1 infection in adults.
  • Currently pregnant (with a single or multiple fetuses)
  • Gestation < 34 weeks
  • No serious current complications of pregnancy
  • Intention to breastfeed
  • Intention to deliver at the institution in which the study is based
  • Other than HIV, no active serious infection, such as tuberculosis or other potentially serious illnesses
  • No previous use of antiretrovirals including the HIVNET 012 regimen
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Malawi
 
NCT00164762
CDC-NCCDPHP-4535, SIP 26-04
No
Not Provided
Centers for Disease Control and Prevention
  • Kamuzu Central Hospital, Lilongwe, Malawi
  • University of North Carolina
Principal Investigator: Sherry L Farr, PhD Centers for Disease Control and Prevention
Principal Investigator: Denise J Jamieson, MD, MPH Centers for Disease Control and Prevention
Principal Investigator: Charles Van der Horst, MD University of North Carolina, Chapel Hill
Principal Investigator: Peter Kazembe, MB ChB Kamuzu Central Hospital
Centers for Disease Control and Prevention
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP